

AdjuTec Pharma AS



An Ultrabroad-Spectrum Drug to Secure the Efficacy of Life-Saving Antibiotics

The Challenge – Fighting Antimicrobial Multi-Resistance (AMR)

AMR, also labelled as the 'silent pandemic', kills 700,000 people yearly, increasing to 10 million deaths in 2050 if we do not act. Gram-negative bacteria protect themselves against antibiotics by producing bacterial enzymes; the two most common are Serine- and Metallo- β -Lactamases (SBL and MBL, respectively). Drugs exist to tackle some SBLs, enabling the antibiotics to work, but there are no clinically approved drugs that selectively inhibit a wide range of MBLs. Importantly, there aren't any approved drugs to simultaneously inhibit SBLs and MBLs, which can coexist in the same pathogen.

The Solution - SECURE

SECURE is the world's first ultrabroad-spectrum inhibitor to simultaneously address MBLs and SBLs. The drug has no antibiotic effect in itself. Instead, it destroys the bacteria's defence mechanisms, making antibiotics work again. This novel drug will uniquely combine the properties from boronic acid derivatives which are proven to inhibit SBLs and a patented MBL inhibitor previously developed by AdjuTec.

The Funding

The team at Neon Innovation helped an incredibly talented medical consortium led by AdjuTec Pharma to secure almost €1.4m in grant funding from the Eureka Eurostars programme. The project will allow the consortium to complete the required preclinical research (in-vitro and in-vivo efficacy/safety) and the First-in-Human clinical study to prove the safety of the drug in humans.

The Impact

Successful completion of the SECURE project will allow this innovative drug to progress to late-stage clinical trials and ultimately reach the patient population. SECURE will be a great addition to the medical arsenal of drugs to combat the spread of AMR. 5 years post-trials, SECURE will save the lives of over 2.3 million patients at risk of serious bacterial infections and generate over €450m in sales, yielding a cumulative income of minimum €200m to the consortium.



eurostars™



30 months



€1.38M Grant



AdjuTec Pharma
AS (NO)
Kappa Solutions
AS (NO)
Clinical Trial
Consultants AB
(SE)
Statens Serum
Institut (DK)

neon
innovation